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Chapter 1: Introduction
As the United States population grays, it faces a myriad of controversial issues
regarding older adults. One such issue is the use of various types of alternative medication,
specifically the use of marijuana as a treatment for a variety of ailments. It is important to
explore all possible routes on how to treat this portion of this population that may be suffering
from different types of illnesses, diseases, and pain that may be more commonplace in older
adults. As a graying nation, there is fundamental importance of being well informed about the
topic of medical marijuana. It is vital to be aware of the existing research, so the best possible
decisions can be made for our elders, loved ones, and ourselves.
In 2011, a national Gallup poll found that 50% of Americans support the legalization
of marijuana (Johannignman & Eschiti, 2013). As more states legalize the drug and accept its
use as a form of medication, the topic is gaining more attention and, consequently, more
criticism. As of 2016, most of the known health benefits to using medical marijuana/cannabis
come from a limited pool of research with an even smaller number of participants, especially
as it pertains to older adults. This leaves today’s society with an abundance of questions
concerning the use of medicinal marijuana for illnesses prevalent in elderly population. Is it
more harmful or helpful? What forms does it come in and do some of those forms of
marijuana work better than others? Does research support marijuana as an illicit substance or
as a beneficial medication? These topics have become increasingly prevalent in today’s
society where the medical use of marijuana is quickly becoming more accepted throughout
the United States. (Denning, 2015).
Whether or not marijuana should be used for medicinal purposes has been a highly
debated topic in the United States that dates back to the 1800s (Kreit, 2003). Kreit (2003)
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states “marijuana was not regulated in the United States (medical or otherwise) until 1941” (p.
1793). Although there was never a consensus of the extent of its efficiency, marijuana was
believed to have therapeutic value and was included in the United States Pharmacopeia until
1941 (Kreit, 2003). Most of the research on marijuana-based drugs was originally conducted
in the 1980s. However, with recent popularization of the usage of cannabis-derived drugs, the
effects and usefulness of marijuana is again being investigated (Johanningman & Eschiti,
2013).
As of 2015, only Colorado and Washington allow the legal use of marijuana both
medicinally and recreationally (Denning, 2015). However, the number of states that are
becoming more accepting of the legal use of marijuana (both recreationally and medically) is
growing (Denning, 2015). Seventeen states, along with the District of Columbia, now have
policies that allow the possession and personal use of marijuana, and 21 states allow
marijuana possession for medical use only (Denning, 2015). Denning (2015) states, “Public
opinion is shifting rapidly as well: three-quarters of Americans support decriminalization for
personal use of marijuana1; 58 percent favor legalization” (p. 568). As more states and
citizens begin to contemplate the issue of marijuana use, the research into the drug’s medical
benefits should follow suit.
Throughout this paper, some terms may be used that have similar definitions. These
terms may be used interchangeably throughout this discussion. The operational definitions of
such terms are as follow:
Operationalization of Terms
Medical (medicinal) marijuana. Bayer (1997) defines medical marijuana as
“Marijuana used to treat pain and other clinical conditions” (p. 1134). However, Reiman,
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Aggarwal, and Reinerman (2014) state that “a drug must be carefully studied in many people
before it can be approved by the FDA. There have not been enough large studies of marijuana
to definitively show that it is a safe and effective drug” (p. 1931). Though used in some states
as a medication, marijuana is not an FDA approved drug.
Cannibis/Ganja. Pudney (2010) describes cannabis (which can be interchangeable
with ganja) as “(or marijuana, hashish, etc.), which derives from the hemp plant cannabis
sativa, particularly the subspecies indica. Products of the cannabis plant are commonly
classified into three main forms: cannabis resin and other extracts (hashish or hash oil);
‘regular’ herbal cannabis (marijuana); and preparations of the female flowering top
(sinsemilla, skunk)”.
Tetrahydrocannabinol (THC). The cannabis plant contains a complex array of
chemical components, but tetrahydrocannibinol (THC) is the primary psycho-active
component in marijuana and the most understood and tested component (Pudney, 2010).
Dronabinol. Dronabinol is a man-made, cannabinoid derived compound that is
approved by the FDA. This drug contains concentrated THC without the risk of other
components found in actual marijuana, which is not approved by the FDA (Ogbru, 2016).
Dronabinal is used to treat illnesses and diseases where some researchers have recommended
the use of medical marijuana.
With the topic of legalizing being so controversial and popular, it is difficult for the
literature and research to keep pace with the ever-changing legalization and acceptance of
medicinal marijuana. The information collected throughout this paper is from the most current
sources available as of summer 2016. It is important to note that readers should continue their
own research as more data regularly becomes available on this subject. By collecting the most
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recent and prevalent information, this paper serves to inform citizens and lawmakers alike
about the lack of research done on the use of medical marijuana and the health benefits
it could lend for diseases in older adults. It will hopefully inspire additional research and
consideration for the drug based on the benefits or its use, especially in older adults.
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Chapter 2: Literature Review
Background on Older Adults in the United States
According to the Profile of Older Americans (2015), the older population is classified
as those persons aged 65 years or older (p. 2). In 2014, there were 46.2 million people aged 65
and older, a 28% increase since 2004 (Profile of Older American, 2015). The percentage of
the population aged 65 and over among the total population increased from 4.1% in 1900 to
13.0% in 2010 and is projected to reach 20.9% by 2050 (West, Cole, Goodkind, & He, 2014).
This segment of the population has and will continue to grow at an accelerated rate (Profile of
Older Americans, 2015).
The Profile of Older Americans (2015) also states, “In 2012-2014, 44% of noninstitutionalized people age 65 and over assessed their health as excellent or very good
(compared to 55% of persons aged 45-65 years)” (p. 12). However, research has also
identified that most older persons have at least one chronic condition and many have multiple
conditions (West et al., 2014). The most common chronic illnesses and impairments reported
from 2011-2014 include: diagnosed arthritis (49% aged 65+), heart disease (31% aged 65+),
stroke (West et al., 2014), diagnosed diabetes (21% aged 65+), hypertension (71% aged 65+
in 2009-2012), cancer (24% aged 65+), and osteoporosis (Profile of Older Americans, 2015;
West et al., 2014). These are diseases/illnesses that have a long duration and generally
progress slowly (West et al., 2014). West et al. (2014) reports that “Among the older
population in 2008, only eight percent had no chronic conditions, compared with 51% who
had one or two, and 41% who had three or more chronic conditions” (p. 36). These conditions
need to be managed on a continual basis. Some chronic conditions can limit people’s
independence and lower their quality of life (Bentler et al., 2009).
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With such a high percentage of elderly individuals experiencing some kind of chronic
illness and the increasing amount of individuals entering this targeted population, the idea of
medical marijuana as an alternative medication needs to be more thoroughly explored.
Research indicates that many elderly individuals experience some kind of chronic illness
and the population of older adults is expected to continue to increase (West et al., 2014).
With this outlook of our population, it is important that we take a look at as many forms
of treatments for chronic illnesses as possible.
Brief Overview of Marijuana
Marijuana derives from the plant Cannabis sativa. It contains more than 400
chemicals, many with unknown effects, which differ from plant to plant. It is the most widely
used drug throughout the United States (Johanningman & Eschiti, 2013). Medical marijuana
differs significantly from most other forms of prescription medications. The U.S. Food and
Drug Administration (FDA) struggles to support the usage of medical marijuana because the
evidence supporting its efficiency varies substantially and, in general, falls short of the
standard for approval largely because there is no way to prescribe an exact amount for
treatment (Johanningman & Eschiti, 2013).
Marijuana as a medication. Marijuana has been used to treat illnesses throughout the
world for hundreds of years (Reinarman, Nunberg, Lanthier, & Heddleston, 2011). However,
it was not until 1839 that Dr. William O’Shaughnessy began to utilize the substance as
medicine. During the mid-19th century into the 21st century, marijuana was prescribed for
therapeutic use in medical practice for a variety of conditions throughout Europe and
subsequently the United States. In 1850, marijuana was admitted to the United States
Pharmacopoeia and listed in the National Formulary and the US Dispensatory (Reinarman et
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al., 2011). It was not until 1936 that the Federal Bureau of Narcotics initiated a law
prohibiting the use of marijuana. Though the American Medical Association urged against the
ban of medical marijuana, Congress passed the law in 1937. The passing of this law, as well
as the increased prescription rates of aspirin and barbiturates, expelled cannabis from the
United States Pharmacopoeia and most medical practice by 1942 (Reinarman et al., 2011). In
the 1960s, after the use of nonmedical cannabis spread, the number of Americans reporting
lifetime usage increased dramatically (Reinarman et al., 2011). Estimates from the 2011
National Survey on Drug Use and Health report that approximately 1.5 million Americans 55
years and older have used this drug, usually without physician involvement (Reinarman et al.,
2011). The sharp increase of marijuana being used recreationally led to the rediscovery of
therapeutic uses of cannabis (Reinarman et al., 2011).
Forms of marijuana.
Inhalation. Marijuana can be consumed in several ways. The first form, and most
common, is by inhalation of smoke. Inhalation of marijuana results in the quickest delivery of
THC and avoids hepatic-pass metabolism. Additionally, smoking marijuana allows for
maximum rapid absorption into the lungs (Johanningman & Eschiti, 2013). Inhalation delivers
a higher percentage of THC into the bloodstream in comparison to other methods of
consumption (Seamon, Fass, Maniscalco-Feichtl, & Abu-Shraie, 2007). McGuinness (2009)
found that when smoked, THC passes quickly from the respiratory tract to the bloodstream
and finds its way to the brain. It then binds to cannabinoid receptors and within minutes, the
active component of the drug affects brain chemistry. The effects will peak approximately 15
to 30 minutes later, but the overall euphoric effects can last up to 3 hours (McGuinness,
2009). Unfortunately, this form of administration is associated with a significant exposure of

10
mutagens, carcinogens, and other toxic products of pyrolysis (Szczniak, Kelly, Whynot, Shek,
& Hung, 2006).
While inhalation seems to be the most common method of administration for
marijuana users, it may not be the best form for older adults using marijuana for medical
purposes as they are less likely than young adults to smoke. In 2010, less than 10% of those
aged 65 and older smoked marijuana and/or tobacco (West et al., 2014). West et al. (2014)
also found that “adverse health outcomes faced by older smokers include a higher risk of
cardiovascular and respiratory diseases, stroke, and cancer (in particular lung and breast
cancer)” (p. 34). Additionally, smoking of any kind in older age can increase your risk of the
following: dementia, osteoporosis, diabetes, erectile dysfunction, macular degeneration,
nuclear cataracts, and skin alterations (West et al., 2014). These enhanced risk factors can
contribute to shorter life expectancy (West et al., 2014).
Ingestion of pill. Another way marijuana is consumed is via ingestion of pill. THC in
pill form is already available and approved by the FDA. However, this form of administration
seems to be less popular in comparison to other forms of consumption. This could be partly
because its euphoric effects are not immediate and cannot be reliably controlled, unlike the
inhalation of smoke (Wilkinson & D'Souza, 2014).
Other. Other forms of consumption include edibles (which provide erratic absorption),
tinctures and tonics, teas and sodas (McGuinness, 2009), hash and wax, and topicals
(Johanningman& Eschiti, 2013). Szczniak et al. (2006) state that “the low aqueous solubility
of cannabinoid compounds poses a challenge for these routes of administration” (p. 161).
Though most of these delivery systems would minimize possible adverse systemic side
effects, they do not deliver THC as directly. When considering the negative side effects of
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inhalation, alternative forms of marijuana consumption seem like the best option when
prescribing marijuana for older adults.
Health Benefits of Medicinal Marijuana
Glaucoma. One of the most common conditions where patients are prescribed
medical marijuana is glaucoma. Glaucoma is a sensory impairment that is more prevalent in
older adults that is caused by elevated intraocular pressure (IOP) (Hall & Degenhardt, 2003).
Often times, glaucoma puts older adults at a greater risk for falls and automobile accidents
(West et al., 2014). Visual impairments increase as people age, and they tend to be more
common in women than in men, especially in the 65 to 84-year-old age group (West et al.,
2014). It has been found that when cannabis or dronabinol (a cannabis-based drug containing
THC) are taken orally or intravenously, they can reduce IOP by up to 25%. However, the
effects are only known to last about three to four hours. (Hall & Degenhardt, 2003).
HIV/AIDS. Another disease in which the cannabis derived drug dronabinol has been
shown to help relieve symptoms of is HIV/AIDS. The reason why dronabinol is so highly
recommended to help with HIV/AIDS is because it stimulates appetite and assists with weight
gain. Dronabinol is currently registered for this medical use in the U.S. (Hall & Degenhardt,
2003). Those with HIV/AIDS who have used dronabinol report that in addition to helping
them gain weight and increase their appetite, dronabinol has also aided them in decreasing
their anxiety and depression, pain, nausea and vomiting (Bottorff et al., 2011). Hall and
Degenhardt (2003) state that there have been anecdotal reports of smoked cannabis being just
as effective in treating HIV/AIDS associated anorexia and weight loss. However, there have
been no controlled studies published as of 2016.
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Cancer and symptoms associated with cancer. Other drugs with a cannabis base that
have been found to aid in relieving nausea and vomiting include nabilone and levonantradol.
These drugs, along with dronabinol, are mostly used by patients who receive chemotherapy
(Hall & Degenhardt, 2003). The most recent information on these drugs reports, that in some
cases, they show more antiemetic efficiency in comparison to other antiemetic drugs on the
market. Conversely, other, newer antiemetics such as ondanseton (ex. Zofran) allow for better
control over nausea and vomiting (Johanningman & Eschiti, 2013). The difference in
efficiency and comparison of side effects is especially apparent when looking at the difference
in smoked cannabis and ondansetron (Johanningman & Eschiti, 2013). One study compared
which drug relieved symptoms of nausea and vomiting induced by syrup of ipecac with the
fewest side effects. While smoked marijuana seemed to initially work the fastest, it also
appeared to have more adverse side effects (Hall & Degenhardt, 2003).
In regards to oncology, marijuana is most often used to reduce pain, increase appetite,
and decrease nausea and vomiting (Johanningman & Eschiti, 2013). Johaningman and Eschiti
(2013) suggest that the THC in marijuana not only helps alleviate some of the symptoms of
some cancers but could actually help stop the development and progression of cancer cells
from spreading. West et al. (2014) reported that over 50% of the population that is diagnosed
with cancer is 65 years old and over making the use of marijuana to treat the unwanted side
effects of chemotherapy especially relevant to older adults.
Multiple Sclerosis and ALS. Cannabis based drugs have also recently been used to
alleviate some symptoms of Multiple Sclerosis (MS) (Bottorff et al., 2011). Patients who have
MS primarily use marijuana to treat lower urinary tract symptoms (mainly urge incontinence).
Investigations have also found marijuana to be helpful in relieving both general symptoms

13
(relaxation of the entire body and stress relief) as well as specific symptoms of MS including
reduction of pain, tremors, numbness, falling/balancing problems, and vertigo (Bottorff et al.,
2011). One study in particular investigated why patients with MS report that painful muscle
spasticity is reduced after using cannabis (Bottorff et al., 2011). Other studies have provided
some support of this finding, but there are too few clinical trials to fully evaluate efficacy
(Hall & Degenhardt, 2003).
Similar symptom relief has been found for those patients who suffer from amyotrophic
lateral sclerosis (ALS). These patients reportedly use marijuana to induce analgesia (inability
to feel pain), muscle relaxation, bronchodilation (decrease the resistance in respiratory
airways and increasing air into the lungs), saliva reduction, appetite stimulation, and sleep
induction (Seamon et al., 2007).
Movement disorders. Marijuana has also been used in the treatment of various
movement disorders to relieve muscle spasms and tics associated with dystonia such as
Parkinson’s disease, Huntington’s disease, and Tourette’s syndrome (Seamon et al., 2007).
One study looked specifically at how marijuana had anecdotal evidence in helping treat
abnormal skeletal muscle movements in the face, limbs, and trunk (Seamon et al., 2007). This
study also showed some positive effects on observer ratings of tremors and tics (Seamon et
al., 2007). However, there has yet to be more than one small study (12 participants), placebocontrolled, single-dose, crossover trial of dronabinol in Tourette’s syndrome (Hall &
Degenhardt, 2003)
Pain and inflammatory disorders. Due to its analgesic and anti-inflammatory
properties, marijuana is often used in a variety of pain disorders, specifically to help relieve
arthritis pain and pain associated with sickle cell disease (Seamon et al., 2007). Arthritis is a
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progressive disorder that, when left untreated, can lead to damage of the joints, disability, and
early mortality (Stone, 2009). In a 2007-2009 Untied States Survey, data revealed that
arthritis was doctor-diagnosed in over 50% of adults aged 65 and older (Cheng et al., 2012).
Stone (2009) found arthritis to be one of the most common health problems we see limiting
activity and independence among older adults. For every 1,000 people aged 65 to 74, 122
reported activity limitations caused by arthritis or other musculoskeletal disorders. It was
further found that number increased to 167 per 1,000 in people aged 75 to 84 and to 281 per
1,000 in those 85 years old and older (Stone, 2009).
Seizures. Marijuana has also been used to help prevent seizures in patients with
epilepsy (specifically those with Dravet’s syndrome) and is believed to have neuroprotective
properties (Seamon et al., 2007). This is important to note because the number of older adults
that have been diagnosed with epilepsy has steadily increased over the last few decades
(Stefan, 2011).
Neurological disorders. In like manner, it is believed that the THC found in marijuana
may slow the progression of Alzheimer’s disease (Seamon et al., 2007). Rafii and Aisen
(2015) note that Alzheimer’s disease is a form of dementia that affects approximately 36
million people worldwide and manifests as progressive memory impairment leading to a
decline in other cognitive abilities, ultimately resulting in complete functional dependency.
Marijuana has also been used to treat other neurological conditions including brain trauma
after concussions and strokes (Seamon et al., 2007). Other ways that cannabis has shown to
physically impact people is by lessening the effects of Hepatitis C, help aid in the painful
effects of inflammatory bowel disease, help regulate metabolism, improve the symptoms of
Lupus and other autoimmune diseases, as well as aid in relieving symptoms of asthma and
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other pulmonary disorders (Seamon et al., 2007). Many neurological diseases, especially
Alzheimer’s, worsen as individuals age making the need for alternative medicines ever more
important.
Mental and emotional disorders. Marijuana has also been used to treat an array of
mental and emotional issues. It has proved to be especially effective in older adults,
particularly veterans, diagnosed with posttraumatic stress disorder (PTSD), anxiety,
depression, schizophrenia, and suicide ideation (Conwell &Thompson, 2008). Risk factors for
suicide among the older population of veterans include major psychiatric illness, particular
personality traits and disorders, physical illness, life event stressors, and functional status
(Conwell &Thompson, 2008).
PTSD. West et al. (2014) found that in 2010, 42% of the total veteran population was
made up of people ages 65 years and older. Additionally, they found that almost 20% of the
veteran population was very near approaching older age (55 to 64 years old). It has been
reported that using marijuana can calm some veterans’ symptoms of hyper arousal that occur
when experiencing flashbacks. Likewise, using marijuana can also help eliminate night terrors
that often occur in people with PTSD (Bonn-Miller, Vujanovic, Boden, & Gross, 2011).
Seamon et al. (2007) further reports that marijuana has been used for the prophylactic and
symptomatic treatment of migraine headaches and phantom limb pain that Veterans often tend
to experience as well as serving as a mood stabilizer.
Most of the health benefits to using medical marijuana/cannabis come from a limited
pool of research with an even smaller number of participants that fall into the age range of
older adults. Further clinical investigation is needed in order to determine the usefulness of
medicinal marijuana as well as how it compares to other drugs.
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Health Risks of Medicinal Marijuana
Side effects. One reason medical marijuana is controversial is because the drug in and
of itself causes unwanted side effects. In 2007, it was reported as the most commonly abused
drug in the Untied States (Seamon et al., 2007). The side effect that is most common for
marijuana usage is damage to the lungs and respiratory system. Cannabis smoke, like tobacco
smoke, is a risk factor for respiratory disease (Seamon et al,, 2007), lung damage, and
possibly cancer (Hall & Degenhardt, 2003). Marijuana smoke contains 50-70% more
carcinogenic ingredients than cigarette smoke that puts people at a higher risk for lung cancer
(Seamon et al., 2007). McGuinness (2009) further notes that marijuana users frequently
experience coughing, respiratory infections, higher rates of asthma, chronic bronchitis
(Seamon et al., 2007), reduced lung density, and lung cysts.
Cardiac. Cardiac side effects are another thing to consider when using marijuana.
Some cardiac side effects include tachycardia (Reese, 2009), syncope, palpitations, orthostatic
hypotension (McGuinness, 2009), (Reese, 2009) stroke, paroxysmal atrial fibrillation
(Seamon et al., 2007), and hypertension (Reece, 2009). Of those aged 65 years and older,
hypertension affects about 50% and tends to be more common in women than men (West et
al., 2014). West et al. (2014) states, “Hypertension, or high blood pressure, is a chronic illness
that can lead to cardiovascular disease (including stroke and coronary heart disease) and heart
failure, as well as kidney failure but because hypertension does not produce obvious
symptoms, over one-fifth of people who have hypertension are unaware of it and thus may not
seek treatment” (p. 38).
Some preliminary evidence also suggests that marijuana can trigger acute myocardial
infarction (Reece, 2009). Patients with cardiovascular disease or who are at risk of stroke or
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myocardial infarction may have an increased risk of cardiovascular effects from marijuana
(Seamon et al., 2007). Researchers also found that using marijuana has been reported as a risk
factor for invasive pulmonary aspergillosis (Seamon et al., 2007). Furthermore, marijuana has
been reported to cause transient ischemic attacks in patients with a low risk of developing
cardiac abnormalities (Seamon et al., 2007). It is important to understand the ways in which
marijuana affects the heart because some older adults experience heart conditions without the
added stress of smoking. West et al. (2014) reports that for every 1,000 people aged 65 to 74,
96 report activity limitations caused by heart or other circulatory conditions with heart disease
being one of the most common. For those aged 75 to 84 the numbers increased to 138 per
1,000 people and 204 per 1,000 people for those aged 85 and over (West et al., 2014).
Disease. Marijuana can also adversely affect older adults with certain diseases, some
of which include: immunosuppression, psychiatric disturbances, cardiac disease, and
respiratory disease (Seamon et al., 2007). Due to marijuana’s suggested immunosuppressive
properties, it may present additional health risks to patients with diabetes, HIV, lupus,
rheumatoid arthritis, cancer, or organ transplants (Seamon et al., 2007). It was also found that
smoking marijuana can suppress the immune system, making it harder to recover from illness
and disease (McGuinness, 2009). When using marijuana, you are at an especially higher risk
of developing head and neck cancers (Seamon et al., 2007). Men in particular should be aware
of the negative side effects of marijuana use as it can debilitate their testosterone levels, sperm
count, and libido (McGuinness, 2009). Sperm from men who are chronic marijuana users
have been found to behave abnormally (McGuinness, 2009).
Psychological and emotional. Other negative side effects that come from smoking
marijuana or using cannabis-derived drugs are psychological or emotional. West et al. (2014)
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reports, “In 2008, 15.7 percent of women and 10.7 percent of men aged 65 and over had
clinically relevant depressive symptoms. The highest share with depressive symptoms was
found among men aged 85 and over (18.9 percent)” (p. 42). Depression is associated with not
only increased mortality, but also increased functional limitations (Seamon et al., 2007).
Marijuana may exacerbate psychiatric disorders in patients with schizophrenia, psychosis,
bipolar disorder, depression, eating disorders, or panic and anxiety disorders and in patients
predisposed to such disorders (Seamon et al., 2007).
Wilkinson’s (2014) research found that there is evidence that marijuana exposure is
associated with an increased risk of psychotic disorders in vulnerable individuals. The
problem in his research was he was unable to identify or formulate a way to identify the
vulnerable at-risk individuals. For those with established psychotic disorders, marijuana use
has a negative effect on the course and expression of the illness. Marijuana has been found to
heighten the symptoms that come with psychosis and schizophrenia (Reece, 2009; Wilkinson
& D’Souza, 2014).
Acute toxic psychosis induced by marijuana may be characterized by hallucinations,
delusions, depersonalization (a loss of the sense of personal identity or self-recognition), fear
of dying, paranoia, anxiety, changes in mood (e.g., depression), altered mental astuteness,
violent behavior, and visual disturbances (Seamon et al., 2007). Those visual disturbances can
often also result in blurred vision, dry eyes, reddening of the conjunctiva, mydriasis, and
photophobia (Seamon et al., 2007).
Depression, anxiety and sleep disturbances. Other negative mental and emotional
side effects include higher risk of depression and anxiety (Reece, 2009). These symptoms are
particularly prevalent in military Veterans and may also have other comorbidities with
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schizophrenia, PTSD, hallucinations, and agoraphobia. It is reported that marijuana users are
four times more likely to develop depression than people who do not use marijuana (Seamon
et al., 2007). Additionally, when marijuana is taken with alcohol, benzodiazepines, or muscle
relaxants, it can result in excessive central nervous system (CNS) depression (Seamon et al.,
2007). It has also been found that chronic marijuana use leads to serious sleep disturbances.
Seamon et al. (2007) states that “CNS effects reported with marijuana include dry mouth, flulike symptoms, nausea, drowsiness, numbness, dizziness, nightmares, and difficulty sleeping”
(p. 1041).
Attention, judgment, and balance. Marijuana usage can also interfere with attention,
judgment, and balance (Reece, 2009). Since marijuana has been shown to cause dizziness, it
may complicate the diagnosis and treatment of vertigo as well (Seamon et al., 2007).
Marijuana use has also been linked to seizures and is believed to have both proconvulsant and
anticonvulsant effects (Seamon et al., 2007). In regards to attention, Dougherty et al. (2013)
found that current and abstinent adult and older adult marijuana users performing a visual
attention task also showed less activity in their right prefrontal, medial and dorsal parietal
cortical regions of the brain. He also found that they showed greater activity in multiple
frontal, parietal, and occipital brain regions relative to controls. This suggests altered
regulation of attention circuitry (Dougherty et al., 2013).
Memory. Rafii and Aisen, (2015) states that Alzheimer’s disease is a form of dementia
that effects approximately 36 million people worldwide and manifests as a progressive
memory impairment leading to a decline in other cognitive abilities, ultimately resulting in
complete functional dependency. Contrary to the findings of Seamon et al. (2007), Dougherty
et al. (2013) found that marijuana use can debilitate one’s memory. He reported that those
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who are heavy marijuana users can develop short-term memory impairments and often show
persistent deficits in recall memory. Dougherty et al. (2013) also stated that, “Poor recall
memory performance in adult marijuana users is accompanied by decreased activity in the
prefrontal cortex, increased activity in the cerebellum, and altered hippocampal lateralization”
(p. 308). Additionally, Seamon et al. (2007) reports that heavy marijuana use can result in
overall psychological dysfunction, affecting a person’s ability to form memories, recall
events, and maintain focus.
Psychomotor performance. Another negative side effect of using cannabis based
drugs or smoking marijuana is the adverse effect it can have on psychomotor performance
(Reece, 2009). It is often advised that those who use such drugs should avoid operating
equipment that might pose danger to themselves or others (ex., driving a car or working with
heavy machinery) while experiencing its effects (Seamon et al., 2007). Hwang, Hong, Hao,
and Jong (2011) found that “Interactions between sensory motor and cognitive aspects of
behavior change as one ages” (p. 716). They additionally stated that, “Age-related
neuromuscular changes result in older adults having muscles that do not respond as well as
those of younger adults” (p. 717).
Other. Other potential negative changes that can be experienced by marijuana users
include changes in mood, distorted sense of time, and a decline in IQ (Reece, 2009). Recent
findings suggest that long-term marijuana exposure is associated with structural brain changes
as well as a decline in IQ (Dougherty et al., 2013; Wilkinson & D’Souza, 2014).
Even though marijuana has a long list of negative side effects it is important to keep in
mind that even pharmaceutical drugs have various negative effects on the human body. The
FDA reports that all medications have side effects and risks. The FDA’s Adverse Event
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reporting system has 2 million reports to date about various negative symptoms associated
with an array of pharmaceutical drugs. Annually, the FDA receives 345,000 reports about
drugs with negative side effects (2000). The research is also contradictory at times. Some
studies show marijuana to help a certain symptom while others find it increases the negative
effect of the same disease.
The benefits and disadvantages of medical marijuana, like with any current
pharmaceutical drug, must be weighed, especially for older adults who may be susceptible to
unwanted side effects. This helps emphasize the importance of increasing the research related
to medical marijuana use in older adults. If we can establish a proper way to prescribe
marijuana and safely establish dosage sizes, marijuana/cannabis derived drugs may be
beneficial as a medication for individuals 65 years and older. However, due to the lack of
scientific research, the benefits and disadvantages cannot be definitively compared.
The stigma associated with marijuana use and potential for addiction and
dependence. Along with health risks, there are various social issues associated with medical
marijuana. The most commonly disputed negative aspect about using marijuana is that it is a
gateway drug and leaves potential for addiction and dependence. Hall and Degenhardt (2003)
argues that the potential adverse effects of long-term cannabis use are of great concern
especially because some medical conditions would require regular cannabis use over periods
of years or even a lifetime. Some health issues that older adults might have for which
marijuana could be prescribed for long periods include glaucoma, MS, spinal cord injuries,
and HIV/AIDS. As with any drug, prescribing marijuana use for such a length of time puts
people at risk for addiction and dependence on the drug. Though the risk of developing
dependence on THC is highest among adults with psychiatric disorders, substance-use
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problems, and other comorbidities, researchers still confirm that any user of the substance
could potentially become addicted or dependent on using it (Hall & Degenhardt, 2003).
Marijuana as a gateway drug. With increased use of marijuana being prescribed as a
medicine, many fear that patients may use this as a gateway drug. A gateway drug is a
substance that opens up potential opportunity of other harmful drugs being used (Seamon et
al., 2007). Oftentimes, gateway drugs are associated with adolescents and teens. However, the
illnesses that call for a prescription of medical marijuana primarily affect older adults, many
fear that we will see much more illicit drug use accompanying it in older populations (Seamon
et al., 2007).
Policy and Legality
Federal policy states that cannabis possession is a criminal offense, and the Drug
Enforcement Agency (DEA) continues to maintain a conservative stance on cannabis use,
calling for it to be classified as a schedule I drug (Johanningman & Eschiti, 2013). The
American Medical Association states that it would support changing the use of cannabis from
a schedule I drug if doing so would facilitate further research and development on
cannabinoid-based medicine (Johanningman & Eschiti, 2013). In fact, many physicians and
advanced practice nurses (APNs) say they would recommend and prescribe marijuana use
more if it was legalized (Johanningman & Eschiti, 2013). Currently, if they do dispense or
prescribe marijuana, practitioners may be charged federally with aiding and abetting
(Johanningman & Eschiti, 2013). The legal use of marijuana is a state-level decision, but
because federal law prohibits possession of marijuana, patients who possess marijuana are
still at risk of being subject to federal criminal charges (Joahnningman & Eschiti, 2013).
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As of 2016, 25 states and the District of Columbia have legalized medical marijuana.
However, more and more states are going through the process of marijuana legalization. In
states where it is legal, patients are only allowed to use and possess small quantities of
marijuana for medical purposes (Johanningman & Eschiti, 2013). However, state laws do not
regulate marijuana’s quality or potency. Therefore, some marijuana may be stronger than
others. Additionally, most states do not address how to obtain the drug (Johanningman &
Eschiti, 2013).
With so many medical professionals in favor of legalization and therapeutic use of
marijuana, it is no wonder why more people are investing time and effort into making medical
marijuana more socially acceptable (Johannignman & Eschiti, 2013). In 2013, a national poll
suggested that up to 50% of Americans support the legalization of cannabis use
(Johannignman & Eschiti, 2013). With these overall positive attitudes towards medical
marijuana legalization, more states have been more accepting of this option (Johannignman &
Eschiti, 2013). However, one of the biggest current concerns about legalizing marijuana is
that legalization would act more as an advertisement or promotion for its use (Johanningman
& Eschiti, 2013). Many are concerned that this will specifically be directed to a younger
population (Johanningman & Eschiti, 2013). Additionally, it is feared that legalization would
increase dependence on the drug. It is estimated that nine percent of users may become
dependent (based off of usage) (Johanningman & Eschiti, 2013).
How a Medication Becomes Legal
Getting a drug federally approved as a new medication is not an easy task. In order for
any drug to become legal, the FDA, not popular vote or state legislature, must approve the
compound and affirm that it is produced according to good manufacturing practice standards,
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distributed by regulated pharmacies, and dispensed in conventional and safe methods
(Wilkinson & D’Souza, 2014). Some law makers believe that if these practices are not put
into place for medical marijuana, states are essentially legalizing recreational marijuana while
forcing physicians to act as gatekeepers for those who want to obtain it (Wilkinson &
D'Souza, 2014). Additionally, those with concerns about legalizing marijuana use would want
the drug to be considered an official medicine (Wilkinson & D’Souza, 2014).
For a drug to become an FDA approved medication, the ingredients in the medication
need to be measureable and consistent with each dose (Wilkinson & D’Souza, 2014). That
means that the same amount of active ingredients, in this case THC, is in one pill (or dose) so
that the health care professionals can evaluate how much and how often a patient should
potentially take the drug (Wilkinson & D’Souza, 2014). One of the issues surrounding
cannabis is that it is a unique drug that can be consumed in many different forms. Each form
has different effects on the body and can make marijuana’s active ingredient (THC) last for
different amounts of time in one’s system (Seamon et al., 2007). Taking into account the
various forms and varying potency of cannabis based drugs, it is apparent why classifying
marijuana as an official medicine, achieving national legalization, and gaining support from
the FDA have been so difficult to accomplish (Seamon et al., 2007).
How much marijuana is a safe amount? One issue that researchers are facing is how
to prescribe quantity and establish potency. What exactly is a safe amount of marijuana to
use? Wilkinson’s (2014) research suggest that there is no clear optimal dose of marijuana that
can be prescribed for its various approved conditions. The amount of THC and other
cannabinoids in each form of marijuana (cigarette, pill, topical, etc.), the size or amount of
these forms, and the quantity consumed by users can vary considerably. Wilkinson (2014)
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further notes that the relative lack of controlled clinical trial data makes finding the
appropriated dose even more challenging. It is also important to remember that marijuana is
approved for mostly chronic conditions that require patients to be on the drug for long periods
of time. However, it is important that physicians be aware of the potential development for
drug tolerance and dependence as well as withdrawal upon the discontinuation of use
(Wilkinson & D'Souza, 2014). All of these factors make it difficult for researchers to establish
guidelines for dosage and administration.
Health care professional’s role. When prescribing medical marijuana, physicians
play a key role in screening patients for potential drug-to-drug interactions as well as
counseling patients about the health risks associated with marijuana use (Seamon et al., 2007).
This step is particularly crucial because many people who are prescribed marijuana have
comorbidities and are likely to be on more than one drug to treat their ailments (Seamon et al.,
2007). Patients with a history of immunosuppression, psychiatric illness, substance abuse
issues, respiratory illness, and cardiovascular disease are urged to avoid marijuana use
(Seamon et al., 2007). This is especially important for older adults who tend to be more
susceptible to illness as they age. Seamon et al. (2007) argues there should also be counseling
put into place for those patients who live alone, drive, or operate heavy machinery, as
marijuana can impair reaction time and motor control (Seamon et al., 2007). Additionally,
people who use marijuana should refrain from using other drugs (alcohol in particular)
recreationally, as the effects of the drugs together may have adverse effects (Seamon et al.,
2007). Patients should also be aware that usage of marijuana might cause significant and
undesirable weight gain and pose further health risks in susceptible patients (Seamon et al.,
2007). Additionally, physicians should consider alternative forms of administration before
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inhalation, as smoking poses many of the same respiratory risks as regular cigarettes (Seamon
et al., 2007).
Pharmacists also play a significant role in the legalization, distribution and use of
medical marijuana (Seamon et al., 2007) because they are currently only allowed to dispense
FDA approved drugs (2015). As of 2016, federal law still renders medical marijuana illegal
meaning pharmacies are not authorized to supply or dispense it. Similarly, physicians cannot
prescribe medical marijuana as a medication. Until it is approved by the FDA, medical
marijuana is a drug that can only be recommended by health professionals. If medical
marijuana is recommended for a patient, they will receive a note from their doctor or (in some
states) an ID card that describes the patient’s diagnosis and the doctor’s recommended
cannabis treatment. If a patient has a note from their physician or ID card, they can then buy
medical marijuana at a dispensary or (in some locations) vending machines (Silverman,
2016).
Some researchers argue pharmacists should conduct in depth background checks of
patients’ medical and social histories, including asking about the possible use of medical
marijuana (Seamon et al., 2007). This is especially crucial if the patient is or has received
drug therapy for a serious chronic or debilitation medical condition or resides in a state where
medical marijuana is illegal (Seamon et al., 2007). With all of these warnings to physicians
and pharmacists alike, Hall and Degenhardt (2003) still contend that marijuana is unlikely to
be prescribed because of the concerns about legal liability. They argue that the least
problematic way of providing medical access to cannabis may be allowing patients with
specified medical conditions an exemption from criminal prosecution to grow cannabis for
their own therapeutic personal use (Hall & Degenhardt, 2003).
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With the increased use of marijuana for health benefits across the United States and
the growing number of states legalizing this substance to be used for medical purposes
(Denning, 2015), leads many to question how and who will be covering the costs of such
medications. It is important to note that costs for medical marijuana come out of the patient’s
pocket as insurance companies won’t cover medications not approved by the FDA
(Silverman, 2016). The Profile of Older Americans found that in 2015 “almost all (93%) noninstitutionalized persons 65+ were covered by Medicare. Medicare covers mostly acute care
services and requires beneficiaries to pay part of the cost, leaving about half of health
spending to be covered by other sources” (13). Medicare does cover some forms of alternative
medicine such as chiropractic care (Wheadon & Song, 2012). Even if the drug did become
legal, financial restrictions may keep some eligible patients from obtaining the drug.
Conclusion
In summary, it is important that we continue to do research on how medicinal
marijuana is harmful and helpful in treating ailments of older adults. As shown in the existing
research, there are many health benefits for using medical marijuana, but the negative side
effects and stigma surrounding marijuana in any form hold many physicians and researchers
back from pursuing legalization further. The social and economic implications of the aging of
the U.S. population will be of significant interest to policy makers and the private sector alike
(West et al., 2014). As population aging continues, the pool of potential individuals who
could benefit from medical marijuana will increase the demand for more discussion on this
topic. The question of what kind of drug marijuana is considered and how it is legally or
illegally accepted still varies state to state. With new forms of the drug that yield fewer
negative side effects, it could be easier to strike a balance between risk and reward.
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Additionally, as more states legalize marijuana, there is greater opportunity to conduct
research case studies on marijuana users and the effect the drug has on them. Researchers and
policy makers alike should take advantage of this available pool of users to further research
and support the discussion towards legalization. In all, medical marijuana is and will continue
to be a controversial topic in need of continuous research and discussion.
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Chapter 3: Recommendations
The purpose of this paper is to showcase the research, however limited, pertaining to
the medical benefits and risks of medical marijuana. My intent is to start conversations among
policy makers, medical professionals, and the general public about medical cannabis in order
to recognize the potential benefit as well as risks to a large percentage of our population.
Starting the conversation will hopefully bring more attention the topic and make it clear that
more research needs to be done to accurately make a judgment on the use of marijuana as a
legal medication.
Based on the findings of my compiled research and the numerous gaps in their results,
I have formulated the following recommendations for future research. These
recommendations not only further the scant research of this important topic but suggest a way
to shape research that is driven toward the goal of finding a legal use for marijuana to aid the
graying population of our nation.
Directing Future Research
Based on the information gathered from the literature review above, it is evident that
there are at least three major gaps in the current research on medical marijuana: (1) lack of a
regulated dosage and potency of the drug, (2) small sample sizes for existing research groups,
and (3) overall lack of extensive study on the effects or benefits. Using these three
shortcomings as guides for future study, researchers can move forward toward the legalizing
medical marijuana to aid the population group that has the most to benefit from it, older
adults.
Establish dosage and potency. Wilkinson and D’Souza (2014) reported that for a
drug to be deemed as medication, the ingredients in the medication need to be measureable
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and consistent with each dose. This is arguably the biggest hurdle to clear before marijuana
can be used as a legal medication. Researchers need to find a way to regulate the amount of
THC in a single dose of marijuana. Not only would this meet the requirements for the FDA, it
could also potentially facilitate more clinical trials. If there is an established dosage and form
of marijuana for researchers to test consistently, the results may be viewed as more reliable
and carry more weight. Establishing a consistent dosage could also aid in answering questions
such as how much is safe for certain ages, how much is safe/helpful for certain ailments, how
effective it is in comparison to other drugs. Once a baseline dosage is established, all of these
questions can be more easily tested.
Expand sample sizes. Much of the existing research to date includes illness-specific
studies with small sample sizes, and not many included participants over the age of 65. In
order to produce more thorough and applicable results, researchers need to expand the sample
sizes for their studies to include more individuals across a wider age range. Very few studies
regarding medical marijuana had participants over the age of 65 years. This could be due to
lack of willing participants, stigmas associated with older adults and marijuana, or researchers
overlooking the older population as medical marijuana users. Involving more of the older
population in studies could balance out data and bridge a gap to addressing further awareness
on the benefits of medical marijuana on older adults. Much of the research on older adult’s
health appears to lack data on alternative forms of medication such as marijuana, but if older
adults were to participate in research and become more informed about the benefits of
medical marijuana specifically for illnesses they experience, this could easily change.
Build upon the small foundation of existing research. The information in the
literature review above was gathered to address the potential health risks and benefits of
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medicinal marijuana on older adults. However, I did not find a single article that addressed
this topic specifically, the reason likely being that the topics of older adults and medical
marijuana are both just gaining a lot interest now because of the baby boomers reaching older
adulthood and medical marijuana being a more highly accepted form of medicine. As
population aging continues, the pool of potential individuals who could benefit from medical
marijuana will increase the demand for more discussion on this topic. With ever changing
laws and views on both older adults and medicinal marijuana, it would be beneficial for
further research on this specific topic to be conducted. Based on the existing research, older
adults have the most to gain from medical marijuana. Many of the diseases where marijuana
is used as treatment are more prevalent in older adults or get worse as the individual ages.
Future research has the potential to further raise awareness and get more people
talking about the benefits of medical marijuana for a variety of illnesses and diseases. The
American Medical Association states that it would support changing the use of cannabis from
a schedule I drug if doing so would facilitate further research and development on
cannabinoid-based medicine (Johanningman & Eschiti, 2013). If more researchers pursue
practical research involving medical marijuana as it pertains to older adults, it is more likely
that policy will follow suit. As stated earlier, many physicians and advanced practice nurses
(APNs) say they would recommend and prescribe marijuana use more if it was legalized
(Johanningman & Eschiti, 2013). As the topic of marijuana becomes more prevalent in
American society, the stigma associated with medical marijuana can be counteracted by
legitimate research aiming to legalize the drug. Pursuing further research into medical
marijuana could have the power to eliminate stigmas about using medical marijuana and
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prove that it can be used as more than just a recreational drug and aid a large percentage of the
population as they enter old age.
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